Research Topics
| N S MajhailSummaryAffiliation: University of Minnesota Country: USA Publications
| Collaborators
|
Detail Information
Publications
Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donorsN S Majhail
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 47:494-8. 2012..UCB is feasible as an alternative donor source for reduced-intensity conditioning HCT among older patients with AML and MDS who do not have a suitable MSD...
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphomaNavneet S Majhail
Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
Br J Haematol 147:129-39. 2009..Compared to the general population, mortality rates continue to remain elevated at 10-years post-transplantation...- A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivorsNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 16:832-7. 2010..Although the number of subjects is small, deferasirox may be a safe and effective alternative for allogeneic HCT survivors with iron overload who cannot undergo phlebotomy... - High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivorsNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:790-4. 2008..More studies are needed to determine the impact of iron overload on long-term morbidity and mortality in allogeneic transplant survivors... - Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplantsNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:985-92. 2008..The HCT-CI, although a useful tool for capturing pretransplant comorbidity and risk-assessment, needs to be further validated prior to adopting it for routine clinical use... - High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantationN S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
Bone Marrow Transplant 43:49-54. 2009..We conclude that metabolic syndrome occurs frequently among allogeneic HCT survivors who are seen by transplant physicians. Approaches to screening, prevention and management of metabolic syndrome should be developed for HCT recipients... - Access to hematopoietic cell transplantation in the United StatesNavneet S Majhail
Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 16:1070-5. 2010..Better understanding of these complex barriers will minimize inequities, inform health policy, guide development of interventions targeted to eliminate disparities, and continue the expansion of HCT in the future... - Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complicationsNavneet S Majhail
University of Minnesota, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 15:564-73. 2009..These costs are primarily driven by severe posttransplant complications, graft failure, and prolonged inpatient stay. Strategies to enhance engraftment will decrease the costs of UCB transplantation... - Costs of pediatric allogeneic hematopoietic-cell transplantationNavneet S Majhail
Adult Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Pediatr Blood Cancer 54:138-43. 2010..Allogeneic hematopoietic-cell transplantation (HCT), although curative for some high-risk diseases, is a complex and costly procedure. The costs of transplantation among children have not been described previously... - Iron overload in hematopoietic cell transplantationN S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 41:997-1003. 2008..Natural history, evolution and treatment of iron overload in transplant survivors have not been adequately investigated and more studies are needed to determine its impact on short-term and long-term morbidity and mortality... - Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donorNavneet S Majhail
Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:282-9. 2008..A careful review of existing comorbidities is necessary when considering older patients for HCT... - Late effects in survivors of Hodgkin and non-Hodgkin lymphoma treated with autologous hematopoietic cell transplantation: a report from the bone marrow transplant survivor studyNavneet S Majhail
Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 13:1153-9. 2007..4, 95% CI 1.0-5.5). HL and NHL survivors of autologous HCT have a high prevalence of long-term health-related complications and require continued monitoring for late effects of transplantation... - High probability of long-term survival in 2-year survivors of autologous hematopoietic cell transplantation for AML in first or second CRN S Majhail
Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA
Bone Marrow Transplant 46:385-92. 2011..Patients who receive autologous HCT for AML in CR1 or CR2 and remain in remission for ≥2 years have very favorable long-term survival. Their mortality rates are similar to that of the general population... 
Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromesNavneet S Majhail
Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 12:1038-46. 2006..28). The pathogenesis of alveolar hemorrhage after HSCT is multifactorial, and we propose that IAH and DAH in HSCT recipients are related clinical syndromes with similar clinical presentation, risks, and associated high mortality...- Alveolar hemorrhage following allogeneic hematopoietic cell transplantation using reduced-intensity conditioningN S Majhail
Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 38:765-8. 2006..Reducing the intensity of preparative regimen does not protect against post transplant alveolar hemorrhage. Alveolar hemorrhage occurring after RIC or MAC HCT has similar incidence, clinical presentation, and associated high mortality... - Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioningNavneet S Majhail
Center for International Blood and Marrow Transplant Research, Minneapolis, MN, USA
Blood 117:316-22. 2011..Recipients of allogeneic HCT using busulfan-cyclophosphamide conditioning are at risk for developing solid cancers. Their incidence continues to increase with time, and lifelong cancer surveillance is warranted in this population... - Allogeneic transplant physician and center capacity in the United StatesNavneet S Majhail
University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 17:956-61. 2011..Our study provides important descriptions of allogeneic transplant activity and capacity of U.S. centers, and our data will assist policy makers plan for the projected growth in the use of transplantation... - Secondary cancers following allogeneic haematopoietic cell transplantation in adultsNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Br J Haematol 154:301-10. 2011..Constructing a patient-specific risk profile based on known exposures and risk-factors is the key to developing appropriate screening and preventative strategies for secondary cancers after allogeneic transplantation... - Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantationNavneet S Majhail
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 15:1100-7. 2009..Continued monitoring and treatment of hypertension and diabetes is necessary in allogeneic HCT survivors, especially in those exposed to high doses of corticosteroids... - Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail
National Marrow Donor Program, Minneapolis, MN 55413 1753, USA
Hematol Oncol Stem Cell Ther 5:1-30. 2012..This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT... - Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantationAhmed Al-Hazzouri
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 14:658-63. 2008..Continuous monitoring of renal function is necessary in allogeneic HCT survivors, and studies exploring prevention strategies are needed... - Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimensA Al-Hazzouri
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 43:949-51. 2009..6 vs RIC). At least in the first few years after HCT, the risks for hypothyroidism are similar among patients receiving TBI-based MA and reduced-intensity regimens... - A modified comorbidity index for hematopoietic cell transplantationT E DeFor
Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 45:933-8. 2010..In conclusion, we are introducing the MCI which may have higher discriminating and predictive power for overall survival and NRM. Validation of the HCT-CI and the MCI in larger and separate cohorts of HCT recipients is still needed... - Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantationN S Majhail
National Marrow Donor Program, Broadway Street NE, Minneapolis, MN 55413 1753, USA
Bone Marrow Transplant 47:337-41. 2012..This report provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT... - Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphomaNavneet S Majhail
Blood and Marrow Transplant Program, Division of Medical and Pediatric Hematology, University of Minnesota, Minneapolis, 55455, USA
Blood 107:3804-7. 2006..67). Our results suggest comparable outcomes for reduced-intensity allo-SCT using UCB or MSD in adults at high risk with advanced Hodgkin lymphoma... - Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphomaNavneet S Majhail
Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 12:1065-72. 2006..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL... - Race and outcomes of autologous hematopoietic cell transplantation for multiple myelomaParameswaran N Hari
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
Biol Blood Marrow Transplant 16:395-402. 2010..Black recipients of AHCT for MM have similar outcomes compared to Whites, suggesting that the reasons underlying lower rates of AHCT in Blacks need to be studied further to ensure equal access to effective therapy... - Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patientsAngela R Smith
Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Blood 117:2728-34. 2011.... - Screening, prevention and management of osteoporosis and bone loss in adult and pediatric hematopoietic cell transplant recipientsB L McClune
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA
Bone Marrow Transplant 46:1-9. 2011.... - Hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphomasNavneet S Majhail
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Mayo Mail Code 286, 420 Delaware St. SE, Minneapolis, MN 55455, USA
Curr Hematol Rep 4:252-9. 2005..Randomized, multi-institutional clinical trials are needed to optimally define the role of stem cell transplantation in PTCL... - The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantationElizabeth A Murphy
National Marrow Donor Program, Minneapolis, Minnesota 55413, USA
Biol Blood Marrow Transplant 16:147-56. 2010..This report summarizes the symposium's deliberations and recommendations to address persistent patient barriers throughout the transplantation process... - Double umbilical cord blood transplantationNavneet S Majhail
Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
Curr Opin Immunol 18:571-5. 2006..Transplantation with two unrelated UCB units is feasible, safe and effective and can overcome the limitation of cell dose of single UCB units... - Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic reviewAmer Beitinjaneh
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Leuk Res 34:831-6. 2010..Although the available literature is limited to observational studies, our systematic review suggests that FLT3 mutations, especially ITD, can adversely affect overall survival and disease-free survival in APL... - Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantationNavneet S Majhail
Biol Blood Marrow Transplant 12:789-91. 2006 - Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancerNavneet S Majhail
Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA
Invest New Drugs 22:421-6. 2004..None of the enrolled patients had an objective response to treatment with continuous infusion rhuIL-4. CONCLUSIONS: A five-day continuous infusion of rhuIL-4 given biweekly is well tolerated with a MTD of 2.0 microg/kg/day...